


1645  
4/16/02  
4/16/02  
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope, with sufficient postage, addressed to: Commissioner for Patents, Washington, D.C. 20231, on

4/8/02


\_\_\_\_\_  
Date of Deposit

Paul E. Rauch, Ph.D.

\_\_\_\_\_  
Name of Applicant, Assignee or  
Registered Representative



\_\_\_\_\_  
Signature

  
4/7/02  
\_\_\_\_\_  
Date of Signature

RECEIVED

APR 12 2002

TECH CENTER 1600/2900

Our Case No.: 10466/76

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ashkenazi et al.

Examiner: To be assigned

Serial No.: 09/904,992

Group Art Unit No.: 1653

Filing Date: July 12, 2001

For: SECRETED AND  
TRANSMEMBRANE  
POLYPEPTIDES AND NUCLEIC  
ACIDS ENCODING THE SAME

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed below and on the attached Form PTO-1449 be considered by the Examiner and

made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

The references now cited are the following:

**OTHER ART**

1. Blast Results A1-A21, GenBank
2. Blast Results, B1-B6, Dayhoff

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these material, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed.

Applicant(s) respectfully request that the listed documents be made of record in the present case.


Respectfully submitted,



---

Paul E. Rauch, Ph.D.  
Registration No. 38,591  
Attorney for Applicant(s)

BRINKS HOFER GILSON & LIONE  
P.O. Box 10395  
Chicago, IL 60610  
(312) 321-4200



Attached herewith is

FORM PTO-1449 <b>U. S. PATENT &amp; TRADEMARK OFFICE</b>	SERIAL NO. 09/904,992	CASE NO. 10466/76
<b>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b>	FILING DATE July 12, 2001	GROUP ART UNIT 1653
(use several sheets if necessary)	APPLICANT(S): Ashkenazi et al.	

### REFERENCE DESIGNATION

## U.S. PATENT DOCUMENTS

TECH CENTER 1600-2900

APR 12 2001  
SECTION NO

RECEIVED

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
A1		Blast Results A1-A21, GenBank
A2		Blast Results, B1-B6, Dayhoff

EXAMINER	DATE CONSIDERED
----------	-----------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.